# Cong Xue

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8884640/publications.pdf

Version: 2024-02-01

| 40 | 1,434 | 567281 15 | 330143 37 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 40 | 40 | 40 | 2926 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptorâ€“Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clinical Cancer Research, 2022, 28, 637-645. | 7.0 | 27 |
| 2 | Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapyâ€” A systematic review and meta-analysis. Clinical Immunology, 2022, 236, 108927. | 3.2 | 4 |
| 3 | Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment. JAMA - Journal of the American Medical Association, 2021, 325, 50. | 7.4 | 113 |
| 4 | A Novel Ferroptosis-Related Gene Signature Predicts Overall Survival of Breast Cancer Patients. Biology, 2021, 10, 151. | 2.8 | 17 |
| 5 | Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2â€positive breast cancer: An openâ€label, doseâ€escalation, phase I study. Cancer Communications, 2021, 41, 171-182. | 9.2 | 15 |
| 6 | Immune checkpoint inhibitor plus anti-EGFR target therapy plus chemotherapy in patients with locally advanced penile squamous cell carcinoma.. Journal of Clinical Oncology, 2021, 39, e17016-e17016. | 1.6 | 2 |
| 7 | Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.. Journal of Clinical Oncology, 2021, 39, 1003-1003. | 1.6 | 10 |
| 8 | Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: Results from the SYSUCC-001 study.. Journal of Clinical Oncology, 2021, 39, 521-521. | 1.6 | 1 |
| 9 | Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Antiâ€“PD-1/PD-L1â€“Based Therapy. Frontiers in Molecular Biosciences, 2021, 8, 621883. | 3.5 | 2 |
| 10 | Treatment Outcome of Different Chemotherapy in Patients With Relapsed or Metastatic Malignant Urachal Tumor. Frontiers in Oncology, 2021, 11, 739134. | 2.8 | 5 |
| 11 | The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial. Journal of the National Cancer Institute, 2020, 112, 55-62. | 6.3 | 19 |
| 12 | Adjuvant chemotherapy for small, lymph nodeâ€“negative, tripleâ€negative breast cancer: A singleâ€center study and a metaâ€analysis of the published literature. Cancer, 2020, 126, 3837-3846. | 4.1 | 20 |
| 13 | Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2019, 173, 619-628. | 2.5 | 9 |
| 14 | Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. Oncologist, 2018, 23, 603-616. | 3.7 | 17 |
| 15 | Efficacy of the hypoxiaâ€activated prodrug evofosfamide (THâ€302) in nasopharyngeal carcinoma in vitro and in vivo. Cancer Communications, 2018, 38, 1-9. | 9.2 | 23 |
| 16 | Two-year follow-up of pretreatment anti-mullerian hormone (AMH) to predict for resumption of mense after chemotherapy in premenopausal hormone-receptor (HR+) positive early breast cancer (eBC).. Journal of Clinical Oncology, 2018, 36, e12511-e12511. | 1.6 | 0 |
| 17 | Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy. Oncotarget, 2017, 8, 5219-5232. | 1.8 | 15 |
| 18 | In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma. Drug Design, Development and Therapy, 2016, 10, 1299. | 4.3 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience. Oncotarget, 2016, 7, 63722-63729. | 1.8 | 2 |
| 20 | Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer. PLoS ONE, 2016, 11, e0148849. | 2.5 | 2 |
| 21 | Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo. Drug Design, Development and Therapy, 2016, 10, 1173. | 4.3 | 1 |
| 22 | A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China. Chinese Journal of Cancer, 2016, 35, 40. | 4.9 | 18 |
| 23 | Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysis. Oncotarget, 2016, 7, 20093-20108. | 1.8 | 31 |
| 24 | Endocrine treatment-related symptoms and outcomes in breast cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2016, 34, e12001-e12001. | 1.6 | 0 |
| 25 | Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment. Scientific Reports, 2015, 5, 10648. | 3.3 | 7 |
| 26 | QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports, 2015, 5, 11934. | 3.3 | 9 |
| 27 | Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma. OncoTargets and Therapy, 2015, 8, 1219. | 2.0 | 4 |
| 28 | Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma. Drug Design, Development and Therapy, 2015, 9, 4897. | 4.3 | 4 |
| 29 | Operable Breast Cancer of the Inner Hemisphere Is Associated with Poor Survival. Journal of Breast Cancer, 2015, 18, 36. | 1.9 | 1 |
| 30 | High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget, 2015, 6, 33972-33981. | 1.8 | 159 |
| 31 | Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma. Chinese Journal of Cancer, 2015, 34, 177-83. | 4.9 | 10 |
| 32 | PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. Oncotarget, 2015, 6, 33019-33032. | 1.8 | 69 |
| 33 | Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. PLoS ONE, 2014, 9, e85245. | 2.5 | 125 |
| 34 | Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials. OncoTargets and Therapy, 2014, 7, 1851. | 2.0 | 15 |
| 35 | Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Design, Development and Therapy, 2014, 8, 1827. | 4.3 | 40 |
| 36 | EBV-driven LMP1 and IFN-Î³ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget, 2014, 5, 12189-12202. | 1.8 | 324 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. OncoTargets and Therapy, 2014, 7, 1475. | 2.0 | 149 |
| 38 | An investigation of symptom burden and quality of life in Chinese chemo-naÃ¯ve advanced lung cancer patients by using the Instrument-Cloud QOL System. Lung Cancer, 2014, 84, 301-306. | 2.0 | 12 |
| 39 | A Large-scale Cross-sectional Study of ALK Rearrangements and EGFR Mutations in Non-small-cell Lung Cancer in Chinese Han Population. Scientific Reports, 2014, 4, 7268. | 3.3 | 28 |
| 40 | National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer, 2012, 77, 371-375. | 2.0 | 112 |